下载掌阅APP，畅读海量书库
立即打开
[1] ZHANG JM，AN J. Cytokines，inflammation，and pain. Int Anesthesiol Clin，2007，45（2）：27-37.
[2] CAVAILLON J M. Pro-versus anti-inflammatory cytokines：myth or reality. Cell Mol Biol（Noisy-le-grand），2001，47（4）：695-702.
[3] DIPIRO J T，HOWDIESHELL T R，GODDARD J K，et al. Association of interleukin-4 plasma levels with traumatic injury and clinical course. Arch Surg，1995，130（11）：1159-1162；discussion 1153-1162.
[4] CSUKA E，MORGANTI-KOSSMANN M C，LENZLINGER P M，et al. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury：relationship to IL-6，TNF-alpha，TGF-beta1 and blood-brain barrier function. J Neuroimmunol，1999，101（2）：211-221.
[5] CHIARETTI A，GENOVESE O，ALOE L，et al. Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv Syst，2005，21（3）：185-193；discussion 194.
[6] KIRCHHOFF C，BUHMANN S，BOGNER V，et al. Cerebrospinal IL-10 concentration is elevated in nonsurvivors as compared to survivors after severe traumatic brain injury. Eur J Med Res，2008，13（10）：464-468.
[7] FERREIRA L C，REGNER A，MIOTTO K D，et al. Increased levels of interleukin-6，-8 and -10 are associated with fatal outcome following severe traumatic brain injury. Brain Inj，2014，28（10）：1311-1316.
[8] ANSARI M A. Temporal profile of M1 and M2 responses in the hippocampus following early 24h of neurotrauma. J Neurol Sci，2015，357（1-2）：41-49.
[9] DI BATTISTA A P，BUONORA J E，RHIND S G，et al. Blood biomarkers in moderate-to-severe traumatic brain injury：potential utility of a multi-marker approach in characterizing outcome. Front Neurol，2015，6：110.
[10] MONDELLO S，SORINOLA A，CZEITER E，et al. Blood-based protein biomarkers for the management of traumatic brain injuries in adults presenting to emergency departments：a living systematic review and metaanalysis. Journal of Neurotrauma，2017，5182.
[11] WANG K K，YANG Z，ZHU T，et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn，2018，18（2）：165-180.
[12] PAPA L，BROPHY G M，WELCH R D，et al. Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol，2016，73（5）：551-560.
[13] ERCOLE A，MAGNONI S，VEGLIANTE G，et al. Current and emerging technologies for probing molecular signatures of traumatic brain injury. Front Neurol，2017，8：450.
[14] Harish G，Mahadevan A，Pruthi N，et al. Characterization of traumatic brain injury in human brains reveals distinct cellular and molecular changes in contusion and pericontusion. J Neurochem，2015，134（1）：156-172.
[15] XU B，TIAN R，WANG X，et al. Protein profile changes in the frontotemporal lobes in human severe traumatic brain injury. Brain Res，2016，1642：344-352.
[16] ABU HAMDEH S，SHEVCHENKO G，MI J，et al. Proteomic differences between focal and diffuse traumatic brain injury in human brain tissue. Sci Rep，2018，8（1）：6807.
[17] CONTI A，SANCHEZ-RUIZ Y，BACHI A，et al. Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin（ogen）degradation products as trauma-associated markers. J Neurotrauma，2004，21（7）：854-863.
[18] HAYTON S，MAKER G L，MULLANEY I，et al. Experimental design and reporting standards for metabolomics studies of mammalian cell lines. Cell Mol Life Sci，2017，74（24）：4421-4441.
[19] JORDAN K W，NORDENSTAM J，LAUWERS G Y，et al. Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum，2009，52（3）：520-525.